<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" >

<channel>
	<title>AI Blood Test Analyzer Free – Lab Interpretation, Made in Germany</title>
	<atom:link href="https://www.kantesti.net/pl/author/emirhan64/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.kantesti.net/pl</link>
	<description>AI Blood Test Analyzer Free – Lab Interpretation, Made in Germany</description>
	<lastBuildDate>Fri, 09 Oct 2026 08:13:06 +0000</lastBuildDate>
	<language>pl-PL</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	
	<itunes:subtitle>AI Blood Test Analyzer Free – Lab Interpretation, Made in Germany</itunes:subtitle>
	<itunes:summary>AI Blood Test Analyzer Free – Lab Interpretation, Made in Germany</itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<item>
		<title>Phenytoin Level: Why Free and Total Results Can Differ</title>
		<link>https://www.kantesti.net/pl/poziom-fenytoiny-wolny-calkowity-albumina-nerki-roznice/</link>
					<comments>https://www.kantesti.net/pl/poziom-fenytoiny-wolny-calkowity-albumina-nerki-roznice/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 08:13:03 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/phenytoin-level-free-total-albumin-kidney-differences/</guid>

					<description><![CDATA[Medication Monitoring Lab Interpretation 2026 Update Patient-Friendly A total phenytoin concentration measures bound and unbound drug together. When protein binding changes, the number on the report may no longer reflect the concentration affecting the brain. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically Reviewed: October 9, 2026 ✅ Evidence-Based [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/poziom-fenytoiny-wolny-calkowity-albumina-nerki-roznice/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dibucaine Number Test: What Low Results Mean for Surgery</title>
		<link>https://www.kantesti.net/pl/test-na-dibukaine-niskie-wyniki-ryzyko-znieczulenia/</link>
					<comments>https://www.kantesti.net/pl/test-na-dibukaine-niskie-wyniki-ryzyko-znieczulenia/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 03:25:47 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/dibucaine-number-test-low-results-anesthesia-risk/</guid>

					<description><![CDATA[Anesthesia Safety Lab Interpretation 2026 Update Patient-Friendly A low dibucaine number can suggest an inherited enzyme variant that prolongs paralysis after succinylcholine or mivacurium. Tell your anesthesiologist before treatment; the result measures enzyme behavior, not how much enzyme activity you have. 📖 ~12 minutes 📅 October 9, 2026 📝 Published: October 9, 2026 🩺 Medically [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/test-na-dibukaine-niskie-wyniki-ryzyko-znieczulenia/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Sweat Chloride Test Results: Borderline and Next Steps</title>
		<link>https://www.kantesti.net/pl/wyniki-testu-chlorkowego-granicze-nastepne-kroki/</link>
					<comments>https://www.kantesti.net/pl/wyniki-testu-chlorkowego-granicze-nastepne-kroki/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 22:36:04 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/sweat-chloride-test-results-borderline-next-steps/</guid>

					<description><![CDATA[Cystic Fibrosis Lab Interpretation 2026 Update Patient-Friendly A borderline sweat chloride result of 30–59 mmol/L does not confirm cystic fibrosis. It means the result needs follow-up: usually repeat testing at an experienced center, review of symptoms and newborn screening, and sometimes CFTR genetic or functional evaluation. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/wyniki-testu-chlorkowego-granicze-nastepne-kroki/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Digoxin Level: Safe Targets, Sample Timing and Toxicity</title>
		<link>https://www.kantesti.net/pl/docelowe-stezenie-digoksyny-czas-pobrania-toksycznosc/</link>
					<comments>https://www.kantesti.net/pl/docelowe-stezenie-digoksyny-czas-pobrania-toksycznosc/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 17:48:11 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/digoxin-level-targets-sample-timing-toxicity/</guid>

					<description><![CDATA[Medication Safety Lab Interpretation 2026 Update Patient-Friendly For heart failure, digoxin levels are usually targeted around 0.5–0.9 ng/mL; for atrial fibrillation, current US guidance recommends below 1.2 ng/mL when levels are measured. Samples generally need at least 6–8 hours after a dose. Toxicity can occur within the laboratory interval, especially with kidney impairment, low potassium [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/docelowe-stezenie-digoksyny-czas-pobrania-toksycznosc/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Lamotrigine Therapeutic Range: Levels and Toxicity Signs</title>
		<link>https://www.kantesti.net/pl/poziomy-terapeutyczne-lamotryginy-objawy-toksycznosci/</link>
					<comments>https://www.kantesti.net/pl/poziomy-terapeutyczne-lamotryginy-objawy-toksycznosci/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 13:00:27 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/lamotrigine-therapeutic-range-levels-toxicity-signs/</guid>

					<description><![CDATA[Medication Monitoring Lab Interpretation 2026 Update Patient-Friendly For epilepsy, many laboratories use 3–15 mg/L as a reference interval; bipolar disorder has no established concentration target. Interpret the result alongside dose timing, symptoms, and interacting medicines—not as an instruction to change your dose. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October 8, 2026 🩺 [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/poziomy-terapeutyczne-lamotryginy-objawy-toksycznosci/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>GAD65 Antibody Positive: Diabetes vs Neurologic Clues</title>
		<link>https://www.kantesti.net/pl/cukrzyca-dodatnia-pod-wzgledem-przeciwcial-gad65-interpretacja-neurologiczna/</link>
					<comments>https://www.kantesti.net/pl/cukrzyca-dodatnia-pod-wzgledem-przeciwcial-gad65-interpretacja-neurologiczna/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 08:12:53 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/gad65-antibody-positive-diabetes-neurologic-interpretation/</guid>

					<description><![CDATA[Autoimmune Diabetes Lab Interpretation 2026 Update Patient-Friendly A positive result can support pancreatic autoimmunity, help investigate a specific neurologic syndrome, or be incidental. The deciding clues are the clinical picture, laboratory method, units, and supporting tests—not the positive flag alone. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October 8, 2026 🩺 Medically Reviewed: [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/cukrzyca-dodatnia-pod-wzgledem-przeciwcial-gad65-interpretacja-neurologiczna/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>ADAMTS13 Activity: Low Results, TTP Risk and Next Steps</title>
		<link>https://www.kantesti.net/pl/adamts13-aktywnosc-niskie-wyniki-ryzyko-ttp/</link>
					<comments>https://www.kantesti.net/pl/adamts13-aktywnosc-niskie-wyniki-ryzyko-ttp/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Thu, 08 Oct 2026 03:24:24 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/adamts13-activity-low-results-ttp-risk/</guid>

					<description><![CDATA[Hematology Lab Interpretation 2026 Update Patient-Friendly ADAMTS13 activity below 10% strongly supports TTP when low platelets and red-cell destruction occur together, but an isolated result does not prove an acute episode. Suspected TTP needs emergency assessment and treatment decisions without waiting for the laboratory result. 📖 ~12 minutes 📅 October 8, 2026 📝 Published: October [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/adamts13-aktywnosc-niskie-wyniki-ryzyko-ttp/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>DPYD Testing Before Chemotherapy: Understanding Results</title>
		<link>https://www.kantesti.net/pl/znaczenie-wynikow-badania-dpyd-przed-chemioterapia/</link>
					<comments>https://www.kantesti.net/pl/znaczenie-wynikow-badania-dpyd-przed-chemioterapia/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 22:35:41 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/dpyd-testing-before-chemotherapy-results-meaning/</guid>

					<description><![CDATA[Chemotherapy Safety Lab Interpretation 2026 Update Patient-Friendly DPYD testing identifies inherited variants that can make fluorouracil or capecitabine dangerously difficult to clear. Results help clinicians choose treatment and starting doses, but a negative genetic screen does not guarantee safety. 📖 ~12 minutes 📅 October 7, 2026 📝 Published: October 7, 2026 🩺 Medically Reviewed: October [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/znaczenie-wynikow-badania-dpyd-przed-chemioterapia/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Carbamazepine Level: Trough Timing, Range and Toxicity</title>
		<link>https://www.kantesti.net/pl/poziom-karbamazepiny-stezenie-minimalne-zakres-toksycznosc/</link>
					<comments>https://www.kantesti.net/pl/poziom-karbamazepiny-stezenie-minimalne-zakres-toksycznosc/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 17:47:56 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/carbamazepine-level-trough-range-toxicity/</guid>

					<description><![CDATA[Medication Monitoring Lab Interpretation 2026 Update Patient-Friendly A result inside the laboratory range is not a safety certificate. The last dose, recent treatment changes and accompanying symptoms can completely change its meaning. 📖 ~12 minutes 📅 October 7, 2026 📝 Published: October 7, 2026 🩺 Medically Reviewed: October 7, 2026 ✅ Evidence-Based This guide was [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/poziom-karbamazepiny-stezenie-minimalne-zakres-toksycznosc/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Tacrolimus Trough Level: Dose Timing, Targets and Toxicity</title>
		<link>https://www.kantesti.net/pl/docelowe-czasy-oznaczenia-stezeniarightsquigarrow-tacrolimus-w-celu-okreslenia-toksycznosci/</link>
					<comments>https://www.kantesti.net/pl/docelowe-czasy-oznaczenia-stezeniarightsquigarrow-tacrolimus-w-celu-okreslenia-toksycznosci/#respond</comments>
		
		<dc:creator><![CDATA[Prof. Dr. Thomas Klein]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 13:00:17 +0000</pubDate>
				<category><![CDATA[Articles]]></category>
		<guid ispermalink="false">https://www.kantesti.net/tacrolimus-trough-level-timing-targets-toxicity/</guid>

					<description><![CDATA[Transplant Medication Safety Lab Interpretation 2026 Update Patient-Friendly A tacrolimus trough level measures the drug in whole blood immediately before your next scheduled dose—usually 12 hours after twice-daily treatment or 24 hours after once-daily treatment. Targets depend on your formulation, transplanted organ and time since transplant; mistimed samples can mislead, and dose changes must come [&#8230;]]]></description>
		
					<wfw:commentrss>https://www.kantesti.net/pl/docelowe-czasy-oznaczenia-stezeniarightsquigarrow-tacrolimus-w-celu-okreslenia-toksycznosci/feed/</wfw:commentrss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>